Sage Therapeutics Inc

NASDAQ: SAGE
$5.94
+$0.13 (+2.2%)
Closing Price on November 5, 2024

SAGE Articles

Sage Therapeutics shareholders took a bath on Thursday after results from its late-stage major depressive disorder trial came public.
Friday's top analyst upgrades and downgrades included Anthem, Ciena, Dollar General, Encana, Lennar, Lululemon Athletica, Sage Therapeutics, Target, Tesla, Trade Desk and Yext.
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.